Where is Dipa located?

Dipa is headquartered in Jakarta, Indonesia.

How many employees does Dipa have?

As of Jul 01, 2024, the latest employee count at Dipa is 402.

Is Dipa a funded company?

Dipa is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Dipa rank among its competitors?

Dipa ranks 584th amongst 876 active competitors, of which 27 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Nivagen Pharmaceuticals, which secured $5M in Aug, 2023.

Who are the top competitors of Dipa?

Dipa's top competitors include Jubilant Life Sciences, Akums and Nivagen Pharmaceuticals. Among them, Nivagen Pharmaceuticals secured the most recent funding round in August, 2023.

Dipa - 2026 Company Profile & Competitors

Company Details

Dipa Pharmalab Intersains is a pharmaceutical company that began as a small pharmaceutical company in 1960 in Jakarta, Indonesia. They offer healthcare solutions and products.

Website: dipa.co.id
Social

Key Metrics

Founded Year

1960

Location

Jakarta, Indonesia

Stage

Unfunded

Ranked

584^th among 876 active competitors

Employee Count

402 as on Jul 01, 2024

Similar Companies

Jubilant Life Sciences & 1089 more

View Dipa's full profile

Dipa has not raised any funding rounds yet.

Dipa's employee count trend

Dipa has 402 employees as of Jul 24. Here is Dipa's employee count trend over the years:

Uncover Dipa's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dipa include Jubilant Life Sciences, Akums and Nivagen Pharmaceuticals. Here is the list of Top 10 competitors of Dipa, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jubilant Life Sciences 1978, Noida (India), Public	Company offering a suite of R&D and manufacturing services for small molecules and generics	-	Samena Capital, General Atlantic & 1 others	59/100
2nd	Akums 2004, Delhi (India), Public	CDMO focusing on spectrum of dosage forms and therapeutic segments	$70M	Quadria Capital & 5 others	58/100
3rd	Nivagen Pharmaceuticals 2009, Sacramento (United States), Acquired	Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution	$31M	Telegraph Hill Partners, BizCap & 1 others	57/100
4th	SAVA group 2003, Pune (India), Unfunded	Pharma company with a portfolio of domestic and export products, also offering CRAMS services	-	-	56/100
5th	Nectar Lifesciences 1995, Chandigarh (India), Public	Manufacturer of cephalosporin APIs and generic formulations	$46.9M	Vedanta Capital, NSR Partners & 1 others	55/100
6th	Recipharm 1995, Jordbro (Sweden), Acquired	Contract services for pharmaceutical development and manufacturing	-	Ampersand Capital, CPP Investments	55/100
7th	Supriya Lifescience 2008, Mumbai (India), Public	Manufacturer of active pharmaceutical ingredients and finished dosage formulations for healthcare	-	-	54/100
8th	Chugai Pharmaceutical 1925, Tokyo (Japan), Acquired	Developer of innovative pharmaceutical products and services	-	Digital Pharma Lab	54/100
9th	Asahi Kasei 1931, Chiyoda-ku (Japan), Public	CDMO focused on manufacturing of liquid, solid & injectable drug formulations	-	Europa	53/100
10th	Alliance 1998, Chippenham (United Kingdom), Public	International consumer healthcare business managing brands and partnerships	-	Eiffel Investment Group, Artemis Investment Management ... & 2 others	52/100
584th	Dipa 1960, Jakarta (Indonesia), Unfunded	Provider of pharmaceutical formulations manufacturing and healthcare services	-	-	23/100